TY - JOUR T1 - Epinephrine use in COVID-19: friend or foe? JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - e1 LP - e1 DO - 10.1136/ejhpharm-2020-002295 VL - 28 IS - 1 AU - Pan Luo AU - Dong Liu AU - Juan Li Y1 - 2021/01/01 UR - http://ejhp.bmj.com/content/28/1/e1.abstract N2 - The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now overwhelming, spreading throughout the world, and has been declared a global pandemic by the WHO. So far, more than 4 million confirmed cases have been reported by WHO worldwide, including more than 290,000 deaths. And the treatment for the critically ill patients of COVID-19 remains a challenge.The first report of pathological characteristics of the patient who died from severe infection with SARS-CoV-2 demonstrated an increased concentration of highly proinflammatory cytokines.1 Actually, the cytokine storm mediated by overproduction of proinflammatory cytokines has been observed in a large population of critically ill patients with COVID-19.2 Cytokine storms can result in cardiovascular collapse, multiple organ dysfunction, cardiac arrest, and death. Epinephrine, a vasoactive agent, has been routinely employed to the critical situation such as cardiac arrest. However, it remains uncertain whether epinephrine can also benefit the cardiac arrest following cytokine storms occurred in … ER -